Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

This study aims to understand how pulmonary arterial hypertension (PAH), which is high blood pressure in the lungs, progresses over time. Researchers want to find new ways to classify how severe PAH is by looking at novel tests, such as inflammatory markers or special heart MRI scans. They will compare these tests to how far people can walk in six minutes. The study includes people aged 18 to 100 years old who have confirmed or suspected PAH, as well as healthy volunteers. The goal is to discover new targets for future treatments. The study status is currently unclear.

Study design: This is an observational study planning to enroll 270 participants. It compares people with PAH to healthy volunteers.
What's involved: Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center. The specific procedures and tests are not detailed.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint, which measures how well novel tests classify disease severity, will be assessed at 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Recruiting

Not specifiedAges 18+Observational

National Institutes of Health Clinical Center (CC)

~270 participants

Updated 2026-09-16 on ClinicalTrials.gov

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Examine whether any novel test (inflammatory markers or high resolution cardiac MRI), accurately classifies PAH subjects according to disease severity as assessed by their baseline 6-minute walk distance.

Measured over 10 years

Conditions

Pulmonary Disease

Pulmonary Hypertension

NCT01730092

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

National Institutes of Health Clinical Center
Bethesda, Marylandstudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Michael A Solomon, M.D. · PRINCIPAL_INVESTIGATOR · National Institutes of Health Clinical Center (CC)

Who to contact

Grace M Graninger, R.N.

[email protected]

(301) 496-9320

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

mean pulmonary artery pressure of \> 25 mmHg at rest,

pulmonary capillary wedge pressure of \< 15 mmHg (or a left ventricular end-diastolic pressure of \< 12 mmHg), and

pulmonary vascular resistance of \> 3 Wood units (240 dyn s cm-5).

Must be eligible for MRI and Gadolinium Based MRI studies

Must be eligible for CT and Iodine Based Contrast CT studies

Exclusion

Pregnant or breastfeeding women (all women of childbearing potential will be required to have a screening urine or blood pregnancy test)

Age less than 18 years

Inability to provide informed written consent for participation in the study

Current pregnancy or breastfeeding (All women of childbearing potential will be required to have a screening urine or blood pregnancy test)

Electrocardiographic evidence of clinically relevant heart disease

Symptoms of coronary or cardiac insufficiency

More than one major risk factor for coronary artery disease (excluding age and sex)

Obesity (defined as a body mass index \> 30 kg/m\^2)

History of underlying conditions/risk factors associated with pulmonary hypertension such as collagen vascular disease, HIV infection, use of appetite suppressants, chronic liver disease or cirrhosis of the liver, chronic thromboembolic disease, congenital heart defects, hypoxemia and/or significant pulmonary parenchymal disease

Systemic hypertension that is not well controlled (i.e. blood pressure at the time of screening \>140/90 mmHg in adults \< 60 years old or \>150/90 mmHg in adults 60 years or older) on medications. Subjects taking \> 2 anti-hypertensive medications will be excluded irrespective of their current blood pressure at time of screening

Anemia, thrombocytopenia or coagulopathy

Renal insufficiency (defined as an estimated glomerular filtration rate of \< 60 mL/min/1.73m\^2 of body surface area)

Active tobacco use (\> 6 months) in the past ten years, any tobacco use within 3 months prior to the screening evaluation or any tobacco use prior to completion of the study

Inability to provide informed written consent for participation in the study

History of recreational drug use with the exception of marijuana (as long as marijuana use was \> 3 months from the time of study screening).

Volunteers may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer.

What this trial measures

Examine whether any novel test (inflammatory markers or high resolution cardiac MRI), accurately classifies PAH subjects according to disease severity as assessed by their baseline 6-minute walk distance.10 years
Compare outcomes in PAH subjects with controls

Trialytics